Mapi - Pharma (Mapi - Pharma) Total Stockholders Equity : $9.48 Mil (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Total Stockholders Equity?

Mapi - Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2015 was $9.48 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Mapi - Pharma's Book Value per Share for the quarter that ended in Jun. 2015 was $1.28. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Mapi - Pharma's Debt-to-Equity for the quarter that ended in Jun. 2015 was 0.00.

Mapi - Pharma Total Stockholders Equity Historical Data

The historical data trend for Mapi - Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Total Stockholders Equity Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Total Stockholders Equity

11.81

10.32

5.46

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Total Stockholders Equity	11.81	10.32	-	5.46	9.48

Mapi - Pharma (NAS:MAPI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Mapi - Pharma's Book Value per Share for the quarter that ended in Jun. 2015 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(9.479	-	0.431)	/	7.057
	=	1.28

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Mapi - Pharma's Debt-to-Equity for the quarter that ended in Jun. 2015 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	9.479
	=	0.00

Mapi - Pharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.